The hold, which was made in response to a serious adverse event report, could impact the company’s plans to start a Phase 3 trial of a combination shot for COVID-19 and influenza.

The results provide the first clinical evidence of RNA editing, a burgeoning field that's drawn interest from biotechs and pharmaceutical companies alike.

Detailed price information for Cosciens Biopharma Inc (CSCI-T) from The Globe and Mail including charting and trades.

The FDA yesterday the approval of Novocure’s Optune device to include the treatment of metastatic non-small cell lung cancer.

QUESTION: Although it says right on the package of baking soda that you can use it for heartburn, if you choose to use it, ...

India’s pharmaceutical industry is projected to hit $42.9b by 2028 with a compound annual growth rate of 6.3% in local ...

The blue blood of threatened horseshoe crabs contains a chemical essential for testing the safety of vaccines. So these ...

The evolution of Pharma 4.0 integrates advanced technologies, transforming drug development and manufacturing with improved ...

Cobenfy's journey from the lab through regulatory approval is a case study in how America's world-class scientists work to ...

Binh Son Refining and Petrochemical Joint Stock Company has awarded Maire with a licensing and Process Design Package for a ...

Trends in gene therapy approvals in recent years are rapidly shaping the future of manufacturing capabilities in the ...

The Utah Office of Professional Licensure Review will be pushing for lower barriers to entry, and an increased focus on ...